Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415531 · ClinicalTrials.gov registry record · Phase 4
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
A Phase 4 study of Hypertension, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 641
- Enrollment target
- 20
- Study locations
NCT01415531 is a Phase 4 study of Hypertension that has completed, run by Forest Laboratories. The registered enrollment target is 641 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01415531, a Phase 4 study of Hypertension, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 641 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nebivolol
Study Locations (20)
California
- Forest Investigative Site 049 - Buena Park
- Forest Investigative Site 034 - Burbank
- Forest Investigative Site 039 - Costa Mesa
- Forest Investigative Site 024 - Fountain Valley
- Forest Investigative Site 020 - Fresno
- Forest Investigative Site 021 - Fresno
- Forest Investigative Site 040 - Greenbrae
- Forest Investigative Site 047 - La Mesa
- Forest Investigative Site 073 - Los Angeles
- Forest Investigative Site 077 - Roseville
- Forest Investigative Site 060 - San Bernardino
- Forest Investigative Site 054 - San Francisco
- Forest Investigative Site 018 - Spring Valley
Arizona
- Forest Investigative Site 065 - Phoenix
- Forest Investigative Site 067 - Phoenix
- Forest Investigative Site 070 - Phoenix
Florida
- Forest Investigative Site 059 - Brooksville
- Forest Investigative Site 033 - Fort Lauderdale
- Forest Investigative Site 006 - Hallandale
Colorado
- Forest Investigative Site 028 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01415531
The ClinicalTrials.gov registry entry for NCT01415531 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01415531 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01415531 about?
NCT01415531 is a clinical study titled "Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)". The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
What is the current status of trial NCT01415531?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 641 participants. The study started on 2011-08. Estimated completion is 2012-04.
What conditions does trial NCT01415531 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT01415531?
The interventions under investigation include: Placebo (DRUG), Nebivolol (DRUG).
Who is sponsoring clinical trial NCT01415531?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01415531 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.